Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sherene Loi

Showing results (61-70 of 325) with videos related to

Pageof 33
Sort By:
Breast Cancer Research : BCR|January 31, 2021
Infiltrating immune cells in benign breast disease and risk of subsequent invasive breast cancerThomas E Rohan, Rhonda Arthur, Yihong Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2006
Molecular forecasting of breast cancer: time to move forward with clinical testingSherene Loi, Christos Sotiriou, Marc Buyse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2012
Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancerFabrice Andre, Maria V Dieci, Peter Dubsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2008
Clinical application of the 70-gene profile: the MINDACT trialFatima Cardoso, Laura Van't Veer, Emiel Rutgers, et al.
Breast (Edinburgh, Scotland)|November 18, 2019
Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trialSteven David, Jennifer Tan, Peter Savas, et al.
Journal of the National Cancer Institute|January 21, 2012
A three-gene model to robustly identify breast cancer molecular subtypesBenjamin Haibe-Kains, Christine Desmedt, Sherene Loi, et al.
Pathology|May 12, 2019
ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in AustraliaGelareh Farshid, Michael Bilous, Adrienne Morey, et al.
Nature Reviews. Clinical Oncology|December 16, 2015
Clinical relevance of host immunity in breast cancer: from TILs to the clinicPeter Savas, Roberto Salgado, Carsten Denkert, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2016
Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancerNathan Touati, Konstantinos Tryfonidis, Franco Caramia, et al.
Asia-Pacific Journal of Clinical Oncology|March 23, 2016
Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscapeJane Beith, Katie Burslem, Richard Bell, et al.
Pageof 33

Showing results (61-70 of 325) with videos related to

Sort By:
Pageof 33
Breast Cancer Research : BCR|January 31, 2021
Infiltrating immune cells in benign breast disease and risk of subsequent invasive breast cancerThomas E Rohan, Rhonda Arthur, Yihong Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2006
Molecular forecasting of breast cancer: time to move forward with clinical testingSherene Loi, Christos Sotiriou, Marc Buyse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2012
Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancerFabrice Andre, Maria V Dieci, Peter Dubsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2008
Clinical application of the 70-gene profile: the MINDACT trialFatima Cardoso, Laura Van't Veer, Emiel Rutgers, et al.
Breast (Edinburgh, Scotland)|November 18, 2019
Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trialSteven David, Jennifer Tan, Peter Savas, et al.
Journal of the National Cancer Institute|January 21, 2012
A three-gene model to robustly identify breast cancer molecular subtypesBenjamin Haibe-Kains, Christine Desmedt, Sherene Loi, et al.
Pathology|May 12, 2019
ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in AustraliaGelareh Farshid, Michael Bilous, Adrienne Morey, et al.
Nature Reviews. Clinical Oncology|December 16, 2015
Clinical relevance of host immunity in breast cancer: from TILs to the clinicPeter Savas, Roberto Salgado, Carsten Denkert, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2016
Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancerNathan Touati, Konstantinos Tryfonidis, Franco Caramia, et al.
Asia-Pacific Journal of Clinical Oncology|March 23, 2016
Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscapeJane Beith, Katie Burslem, Richard Bell, et al.
Pageof 33